The Patent Finder

Rheogene, Inc.

Also on record
Records under this name other than the patents Rheogene, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 1 patents it holds.

Back to Rheogene, Inc.

PatentTitleStatus Expires Confidence
US 8,715,959Novel substitution mutant receptors and their use in a nuclear receptor-based inducible gene expression system
Term ended
Ended no later than Nov 6, 2025 · Medium confidence
Term endedEnded no later than Nov 6, 2025Medium confidence
US 7,456,315Bioavailable Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex
Term ended
Ended no later than Apr 22, 2025 · Medium confidence
Term endedEnded no later than Apr 22, 2025Medium confidence
US 9,493,540Novel ecdysone receptor/invertebrate retinoid X receptor-based inducible gene expression system
Formerly held
Lapsed on the fee record
Ended Nov 15, 2024 · High confidence
Lapsed on the fee recordEnded Nov 15, 2024High confidence
US 8,691,527Substitution mutant receptors and their use in a nuclear receptor-based inducible gene expression system
Formerly held
Term ended
Term ended Aug 19, 2024 · From the USPTO record
Term endedTerm ended Aug 19, 2024From the USPTO record
US 7,375,093Ketone Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex
Term ended
Term ended Mar 14, 2024 · High confidence
Term endedTerm ended Mar 14, 2024High confidence
US 8,129,355Ketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
Lapsed on the fee record
Ended Mar 6, 2024 · From the USPTO record
Lapsed on the fee recordEnded Mar 6, 2024From the USPTO record
US 7,563,928Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
Term ended
Ended no later than Feb 26, 2024 · From the USPTO record
Term endedEnded no later than Feb 26, 2024From the USPTO record
US 8,524,948Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
Term ended
Ended no later than Feb 26, 2024 · From the USPTO record
Term endedEnded no later than Feb 26, 2024From the USPTO record
US 9,255,273Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
Lapsed on the fee record
Ended Feb 9, 2024 · From the USPTO record
Lapsed on the fee recordEnded Feb 9, 2024From the USPTO record
US 9,249,207Novel substitution mutant receptors and their use in an ecdysone receptor-based inducible gene expression system
Formerly held
Lapsed on the fee record
Ended Feb 2, 2024 · High confidence
Lapsed on the fee recordEnded Feb 2, 2024High confidence
10 of 33 patents shown.
Pro members see all 33.
Pro members: see all 33 patents
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited